The Foundation for Prader-Willi Research

Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2017 by Tien Lee. The company focuses on developing and commercializing small molecule therapeutics specifically targeting obesity and rare genetic metabolic disorders. Its lead product, Bittera, is a first-in-class oral composition designed to selectively disrupt hunger signaling while regulating energy homeostasis, providing a novel treatment option that does not interfere with nutrient absorption. Through its innovative approach, Aardvark Therapeutics aims to offer effective and safe solutions for clinicians managing obesity-related diseases.

Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, founded in 2017 by Tien Lee. The company focuses on developing and commercializing small molecule therapeutics specifically targeting obesity and rare genetic metabolic disorders. Its lead product, Bittera, is a first-in-class oral composition designed to selectively disrupt hunger signaling while regulating energy homeostasis, providing a novel treatment option that does not interfere with nutrient absorption. Through its innovative approach, Aardvark Therapeutics aims to offer effective and safe solutions for clinicians managing obesity-related diseases.

Beryl Therapeutics goal is to open up a new frontier in bone health based on the revelation that lipids are crucial signaling molecules that play a role in bone mass regulation. Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density caused by disease or natural aging.

Lipidio Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapeutics to address diseases associated with excess body fat. Founded in 2018, the company is advancing a lead candidate, GDD3898, for the treatment of various conditions, including Prader-Willi syndrome, nonalcoholic steatohepatitis, and antipsychotic drug-induced weight gain. In addition to its metabolic focus, Lipidio is also exploring applications for dermatological conditions such as sebaceous hyperplasia and moderate to severe acne. By targeting these medical needs, Lipidio Pharmaceuticals aims to provide effective treatment options for patients affected by obesity and related disorders.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.